Prosecution Insights
Last updated: November 04, 2026
Application No. 18/913,158

Radiopharmaceutical Compositions of Radioactive Halogenated Benzylguandine

Non-Final OA §103§112§DOUBLEPATENT
Filed
Oct 11, 2024
Priority
Jun 22, 2018 — provisional 62/688,470 +2 more
Examiner
DONOHUE, SEAN R
Art Unit
Tech Center
Assignee
Jubilant Draximage Inc.
OA Round
1 (Non-Final)
41%
Grant Probability
Moderate
1-2
OA Rounds
1y 3m
Est. Remaining
62%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
305 granted / 736 resolved
-18.6% vs TC avg
Strong +21% interview lift
Without
With
+21.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
52 currently pending
Career history
809
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
52.2%
+12.2% vs TC avg
§102
9.9%
-30.1% vs TC avg
§112
20.5%
-19.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 736 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
DETAILED ACTION This Office action details a first action on the merits for the above referenced application No. Claims 1-20 are pending in this application. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application is a 35 USC 111(a) filing that claims benefit under 35 USC 120 as a continuation of US application No. 17/831,698 filed on 3 Jun. 2022, which is a continuation of US application No. 16/447,155 filed on 20 Jun. 2019, now US 11,351,276, which claims benefit under 35 USC 119(e) to US provisional application No. 62/688,470 filed on 22 Jun. 2018. Information Disclosure Statement An information disclosure statement (IDS) has not been filed with the instant application No. Claim Objections Claims 1-2 and 13 are objected to because of the following informalities: in claims 1-2 and 13, the periods at “5±3oC.” and “-78±3oC.” should be removed. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2 and 10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 2, it is not clear if claim 2 further limits claim 1 since claim 1 requires a radiochemical purity of at least 97% following 4 d of storage at 5±3oC after its preparation. Regarding claim 10, the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-10, and 12-18 is/are rejected under 35 U.S.C. 103 as being unpatentable over Charleson (US 4,880,615 A; published 14 Nov. 1989; see attached 892), in view of Janssen et al. (US 2009/0005595 A1; published 1 Jan. 2009; see attached 892) and Kvaternik et al. (NuklearMedizin; published 2011; see attached 892). Charleson teaches stabilized radiopharmaceutical compositions (see title). Charleson teaches that ascorbic acid, nicotinic acid or nicotinamide either alone or in combination when incorporated into radiopharmaceutical containing radioactive iodine unexpectedly retard radiolytic decomposition caused by radioactive decay of iodine thereby prolonging their useful shelf-life (see col. 1). Charleson teaches antimicrobial agents (col. 1). Charleson teaches that in combination with nicotinic acid or nicotinamide, ascorbic acid is added in equimolar amounts with nicotinic acid or nicotinamide (ratio 1:1)(col. 2). Charleson teaches solution 33-6 having activity 54.8 mCi, 6.8 mL, specific concentration 8 mCi/mL, stabilizer nicotinamide at 16 mg/mL wherein the solution maintained a radiochemical purity of 94% up to 11 d and wherein the solution has 0.005 M acetate buffer pH 5.0 and is stored at room temperature and wherein the radiochemical purity is at least 98% immediately following its preparation (table 1). (reads on a sterile aqueous radiopharmaceutical composition, comprising 123I-m-iodobenzylguanidine (131I-mIBG); an acetate buffering agent wherein the radioactivity concentration is 8 mCi/mL wherein the composition has a radiochemical purity of at least 98% at the time immediately following its preparation from its constituent ingredients wherein the composition has a radiochemical purity of a least 95% at following 4 d of storage at room temperature after preparation from its constituent ingredients; and wherein the composition is from of any other radioprotectant selected from parabens, ascorbic acid, and gentisic acid and wherein the nicotinamide is present in a 0.0016 g/mL and wherein the composition is a solution and wherein the container is a vial.) The compounds will act as scavengers for radicals produced by radiolytic decomposition (col. 1). Charleson does not disclose the claim compositions further comprising benzyl alcohol so that the combination of benzyl alcohol and nicotinamide is in a ratio of about 1:0.8 to 1:32 by weight as a radioprotectant; a sodium chloride isotonic agent; a radioactivity concentration of about 20 mCi to about 1 Ci/mL, a radiochemical purity of at least 99% immediately following preparation, and a radiochemical purity of 97% following 4 d of storage at 5oC optionally wherein the radiochemical purity 2 d after its preparation is at least 95% when stored between -78±3oC and 25±3oC optionally wherein 131I-mIBG is at 0.1 mg/mL to 10 mg/mL, optionally wherein the benzyl alcohol is at from 0.9% (v/v) to 2.0% (v/v), optionally wherein the nicotinamide is present from 0.5 g/100 mL to 10 g/100 mL, optionally wherein the benzyl alcohol and niacinamide is in the ratio of 1:1 to 1:5 by wt or 1:1.8 by weight. Charleson does not teach that the composition is prepared by a method comprising the steps of (i) combining benzyl alcohol with water to form a solution, (ii) adding niacinamide to the solution of step (i), and mixing; (iii) adjusting the pH of the solution from 4 to 6; (iv) adding 131I-m-iodobenzylguanidine to the pH adjusted solution of step (iii), and (v) aseptically filtering the solution of step (iv) through a membrane filter and dispensing the filtered solution into vials under asceptic conditions. Janssen et al. teach gentisic acid for stabilizing 123-I radiopharmaceuticals (see title). Janssen et al. teach that suitable antimicrobial preservatives include benzyl alcohol ([0046]). Radioiodinated phenols may be stabilized with benzyl alcohol ([0005]). The radiopharmaceuticals of the invention may be prepared by asceptic manufacture to give the desired sterile, pyrogen free product. The radiopharmaceuticals may be prepared under non-sterile conditions, following terminal sterilization using membrane filtration (sometimes called sterile filtration) ([0050]). Janssen et al. teach example 5 where to each vial an aliquot of 0.5 cm3 of freshly prepared 123I-mIBG in stabilizer free phosphate buffer was added and subsequently an aliquot of an aqueous phosphate buffer solution containing a stabilizer as specified in table 4 followed by mixing. Vials A1 to E1 were stored at 40oC and vials A2 to E2 at 20oC. The RCP was determined at the EOS and at 3, 20, and 45 h thereafter. Vials A1 and A2 contained 0.8% benzyl alcohol (example 4). Janssen et al. teach a preferred pH between 5.4 and 7 and storage in the dark at 2 to 8o C([0067]-[0068]). Janssen et al. teach radioactivity concentrations between 8 to 1000 MBq/cm3 ([0042]). Janssen et al. teach sodium chloride ([0048]) and isotonic saline ([0040]). Janssen et al. teach a Teflon coated rubber stopper ([0085]). Kvaternik et al. teach an improvement in the synthesis of NCA 131ImIBG (see title). Kvaternik et al. teach that for stabilization, 0.3 mg of dihydrobenzoic acid was added to the isolated phosphate buffered saline pH 4.5/ethanol/benzyl alcohol 10 mg/mL. The radiochemical purity in all preparations were almost >99% and the formulations were stable over a period of more than 20 h (see abstract). It would have been obvious to a person of ordinary skill in the art before the effective filing date to modify the compositions of Charleson (a sterile aqueous radiopharmaceutical composition comprising 131I-mIBG, phosphate buffer, niacinamide at 16 mg/mL wherein the radioactivity of the composition is about 8 mCi/mL wherein the composition has a radiochemical purity of at least 98% at the time immediately following its preparation from its constituent ingredients, wherein a composition has a radiochemical purity of at least 95% following 4 d of storage at room temperature after is preparation from its constituent ingredients, wherein the composition is at pH 5, and wherein the composition is free of other radioprotectant selected from parabens, ascorbic acid and gentisic acid and wherein the composition is in a vail and the optional composition wherein niacinamide and second anti-radiolytic stabilizer are in a 1:1 molar ratio) so that the niacinamide is combined with benzyl alcohol such that the benzyl alcohol and niacinamide are in about an equimolar ratio such as 1:1 or 1:1.8 by weight and so that the composition comprises isotonic sodium chloride as taught by Charleson., Janssen et al., and Kvaternik et al. because the benzyl alcohol would have been expected to advantageously provide an antimicrobial and radiostabilization by an additional mechanism and because the sodium chloride would have been expected to provide isotonicity. It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify the compositions of Charleson so that the composition has a radiochemical purity of at least 99% at the time immediately following its preparation from its ingredients as taught by Janssen et al. and Kvaternik et al. because it would have been expected to enable high radiochemical purity from the outset whereby prolonging composition shelf-life A composition and its properties are inseparable. The compositions taught and motivated by Charleson, Janssen et al., and Kvaternik et al. is the same as the compositions disclosed in the specification that enable a radiochemical purity of at least 97% following 4 d of storage at 5±3oC after its preparation and the radiochemical purity 2 d after its preparation is at least 95% when stored between -78±3oC and 25±3oC. Differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). A person of ordinary skill in the art would have arrived at a 131I-mIBG concentration from 0.1 mg/mL to 10 mg/mL in order to arrive at an effective amount of the 131I-mIBG. A person of ordinary skill would have arrived at a benzyl alcohol concentration from 0.9% (v/v) to 2% (v/v) in order to arrive at an effective amount of benzyl alcohol for radiostabilization and antimicrobial activity. A person of ordinary skill in the art would have arrived at a niacinamide concentration from 0.5 g/100 mL to 10 g/100 mL in order to arrive at effective amount that retards radiolytic decomposition of the 131I-mIBG. A person of ordinary skill in the art would have arrived at a ratio of benzyl alcohol and niacinamide of about 1:1 or 1:1.8 through routine experimentation in order to provide optimal radiolysis inhibition. Claim 7 is a product by process claim. Product by process claims are not limited to the manipulations of the recited steps, only the structure implied by the steps. MPEP 2113. It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify Charleson by further aseptically filtering the solution of step (iv) through a membrane filter and dispensing the filtered solution into vials under asceptic conditions as taught by Janssen et al. because the filtering and dispensing would have been expected to enable terminal sterilization and composition suitable for administration to mammalian subjects. It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify Charleson so that the composition is in vial containing a Teflon coated stopper as taught by Janssen et al. because that vial would have been expected to enable a container suitable for containing the obvious radiopharmaceutical composition. Claim(s) 1-10, and 12-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over Charleson (US 4,880,615 A; published 14 Nov. 1989; see attached 892), in view of Janssen et al. (US 2009/0005595 A1; published 1 Jan. 2009; see attached 892) and Kvaternik et al. (NuklearMedizin; published 2011; see attached 892) in further view of Sharp et al. (Radiographics; published 12 Jan. 2016; see attached 892). Charleson teaches as discussed above. Charleson does not further teach a method for diagnosing, detection or localization in a subject of neuroblastoma, the method comprising administering to the subject the radiopharmaceutical composition and performing scintigraphic imaging. Janssen et al. teach as discussed above. Kvaternik et al. teach as discussed above. Sharp et al. teach MIBG in neuroblastoma diagnostic imaging and therapy (see title). Sharp et al. teach 125I-MIBG is the first line functional imaging agent used in neuroblastoma imaging. MIBG uptake is seen in 90% of neuroblastomas, identifying both primary and sites of metastatic disease. Therapeutic use of MIBG labeled with iodine-131 (131I) is being investigated as part of research trials, both as a single agent and in conjunction with other therapies (see abstract). Sharp et al. teach administration of 123I-MIBG and 131I-MIBG and scinitgraphic imaging (pg. 262, Fig. 1; pg. 265, Fig. 6). It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify Charleson by further administering the 131I-mMIBG radiopharmaceutical composition made obvious by Charleson, Janssen et al. and Kvaternik et al. to the subject having neuroblastoma and imaging the subject by scintigraphy as taught by Sharp et al. because it would have been expected to advantageously enable identifying or treating neuroblastoma in the subject using a composition with optimal RCP and shelf-life. Claim(s) 1-18 is/are rejected under 35 U.S.C. 103 as being unpatentable over Charleson (US 4,880,615 A; published 14 Nov. 1989; see attached 892), in view of Janssen et al. (US 2009/0005595 A1; published 1 Jan. 2009; see attached 892) and Kvaternik et al. (NuklearMedizin; published 2011; see attached 892), in further view of Ahlem et al. (US 2006/0079492 A1; published 13 Apr. 2006; see attached 892). Charleson teaches as discussed above. Charleson does not further teach a 30 mL type I glass vial with a Teflon-coated butyl rubber stopper. Janssen et al. teach as discussed above. Kvaternik et al. teach as discussed above. Ahlem et al. teach compositions and treatment methods (see title). Ahlem et al. teach 131I-labeled compounds ([0563]). Ahlem et al. teach drug solution dispensing into type I glass vials with Teflon coated stoppers (example 1). It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify Charleson so that the obvious composition is packed in a 30 mL type I glass vial capped with Teflon-coated, butyl rubber stopper as taught by Ahlem et al. because the that vial would have been expected to provide an pharmaceutical vial suitable for containing an effective amount of the obvious compositions. MPEP 2144.05.II. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of U.S. Patent No. 11,351,276 B2, in view of Janssen et al. (US 2009/0005595 A1; published 1 Jan. 2009; see attached 892), and Ahlem et al. (US 2006/0079492 A1; published 13 Apr. 2006; see attached 892). Claims 1-16 of U.S. Patent No. 11,351,276 B2 claim a pharmaceutical composition comprising 131I-mIBG and radioprotectants benzyl alcohol and niacinamide, wherein the benzyl alcohol and niaincamide are present in the ratio of about 1:0.8 to 1:32, optionally 1:1 or 1:1.8 wherein the composition has a pH of 5, wherein the radioactivity concentration of the composition is about 20 mCi/mL to about 1 Ci/mL, wherein the composition has a radiochemical purity of at least 99% at the time immediately following its preparation from its constituent ingredients and wherein the composition has a radiochemical purity of at least 97% following 4 d of storage at 5±3oC wherein the composition does not include paraben, optionally wherein the benzyl alcohol is present from 0.9% (v/v) to 2.0% (v/v), optionally wherein the solution comprises sodium chloride and wherein composition is provide in a vial. Claims 1-16 of U.S. Patent No. 11,351,276 B2 claim a method for diagnosing, detection and localization in a subject a neuroblastoma comprising administering the subject the radiopharmaceutical composition according to claim 1 and performing scintigraphic imaging. Claims 1-16 of U.S. Patent No. 11,351,276 B2 do not claim a radiochemical purity of the composition 2 d after is preparation is at least 95% when stored between -78±3oC and 25±3oC or wherein the 131I-mIBG is at 0.1 mg/mL to 10 mg/mL or wherein the niacinamide is present from 0.5 g/100 mL to 10 g/100 mL. Claims 1-16 of U.S. Patent No. 11,351,276 B2 do not claim that the composition is prepared by a method comprising the step (v) aseptically filtering the solution of step (iv) through a membrane filter and dispensing the filtered solution into vials under asceptic conditions. Claims 1-16 of U.S. Patent No. 11,351,276 B2 do not claim that the composition is packed in a 30 mL type I glass vial capped with Teflon-coated rubber stopper. Janssen et al. teach as discussed above. Ahlem et al. teach as discussed above. It would have been obvious to a person of ordinary skill in the art before the effective filing date to modify claims 1-16 of U.S. Patent No. 11,351,276 B2 so that it has a radiochemical purity of at least 95% 2 d following preparation when stored between -78±3oC and 25±3oC and so that the he 131I-mIBG is at 0.1 mg/mL to 10 mg/mL and so that the niacinamide is present from 0.5 g/100 mL to 10 g/100 mL and so that the composition is prepared comprising the step of asceptically filtering the solution of step (iv) through a membrane filter and dispensing the filtered solution into vials under asceptic conditions as taught by Janssen et al. because it would have been expected to effective composition of 131ImIBG having an optimal shelf-life while being suitable for administration to subjects. MPEP 2144.05.II. It would have been obvious to a person of ordinary skill in the art before the effective filing date to further modify claims 1-16 of U.S. Patent No. 11,351,276 B2 so that the composition is packed in a 30 mL Type I glass vial capped with Teflon coated, butyl rubber stopper as taught by Ahlem et al. because the that vial would have been expected to provide an pharmaceutical vial suitable for containing an effective amount of the obvious compositions. MPEP 2144.05.II. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEAN R DONOHUE whose telephone number is (571)270-7441. The examiner can normally be reached on Monday - Friday, 8:00 - 5:00 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached on (571)272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Michael G. Hartley/Supervisory Patent Examiner, Art Unit 1618 /SEAN R. DONOHUE/ Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Oct 11, 2024
Application Filed
Oct 07, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779058
RADIOLABELED SUGARS FOR IMAGING OF FUNGAL INFECTIONS
4y 9m to grant Granted Nov 03, 2026
Patent 12709601
RADIOLABELLED COMPOUND
5y 10m to grant Granted Aug 18, 2026
Patent 12685789
NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF
1y 6m to grant Granted Jul 21, 2026
Patent 12679812
18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS
4y 11m to grant Granted Jul 14, 2026
Patent 12661415
ISOINDOLINONE COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN
4y 2m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
41%
Grant Probability
62%
With Interview (+21.0%)
3y 3m (~1y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 736 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month